Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2005

View Archived Issues

Anti-Alzheimer's effect of statins may be mediated via antiinflammatory effects on microglia

European approval for NovoMix 50 and NovoMix 70 insulin analogues

GenPat77 receives grant to advance CEACAM1 into clinical testing

Phase III Photrex study for wet AMD begins enrollment

Treatment completed in phase I/II study of GTP-200 for cancer cachexia

Medtronic submits first PMA module for Endeavor stent

Eisai and TorreyPines sign new Alzheimer's research agreement

Myriad Genetics plans preclinical data submission for antithrombin drug

Phase II trial begins for CDA-1 for C. difficile-associated diarrhea

Treatment completed in phase II/III trial of Diamyd

VIRxSYS completes financing

Phase III Evamist study completes enrollment

Chugai patent describes new vitamin D receptor agonists for urological disorders

Novel agents for treating endocrine-related disorders disclosed in recent patents

HCV protease inhibitors claimed in recent Vertex patent

Recent Lilly and Bayer patents report novel agents for obesity and lipoprotein disorders

5-HT3 receptor antagonists suppress beta-amyloid-induced neurotoxicity

Preclinical data on peptide YY3-36

Rho kinase inhibitor improves responses of the cavernosal smooth muscle in rats

A-317567 -- First blocker of ASICs implicated in pain pathways

Update on the cardiac benefits of istaroxime

Seibule approved in Japan for postprandial hyperglycemia

Topical tacrolimus reported effective in children with atopic dermatitis

Gemifloxacin shows efficacy in acute bacterial sinusitis and AECB

Japan approves fluvoxamine maleate for social anxiety disorder

Ebixa receives European approval for moderate Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...